That's the thing though, it's an ex-vivo trial so they won't be treating any UTI patients. Basically, they will collect urine from the healthy patients and then add bacteria to it.
I'm wonder whether the market will be excited about ex-vivo results. And I hope the FDA and ethics committee will be satisfied with the data to allow a phase 3 to proceed next year.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)